Table 3:
Top 15 cancer incidence, mortality rates, and 95% confidence intervals by urban, large rural, and small rural location Oklahoma 2016–2020
| Incidence | ||||||||
|---|---|---|---|---|---|---|---|---|
| Urban | Large Rural | Small Rural | ||||||
| Cancer | AAIR | 95% CI | Cancer | AAIR | 95% CI | Cancer | AAIR | 95% CI |
| Female Breast (Excluding In Situ) | 68.7 | 67.3–70.1 | Lung and bronchus | 70.4 | 68.4–72.4 | Lung and bronchus | 64.7 | 61.6–67.8 |
| Lung and bronchus | 60.2 | 59.0–61.4 | Female Breast (Excluding In Situ) | 61.0 | 59.0–63.0 | Female Breast (Excluding In Situ) | 54.1 | 51.1–57.1 |
| Prostate | 49.3 | 48.2–50.4 | ColoRectal | 43.5 | 41.8–45.2 | ColoRectal | 45.7 | 43.0–48.4 |
| Melanomas of the skin | 42.0 | 40.9–43.1 | Prostate | 40.3 | 38.8–41.8 | Prostate | 43.7 | 41.2–46.2 |
| ColoRectal | 38.6 | 37.6–39.6 | Melanomas of the skin | 35.1 | 33.6–36.6 | Melanomas of the skin | 30.9 | 28.7–33.1 |
| Kidney and renal pelvis | 20.5 | 19.8–21.2 | Kidney and renal pelvis | 22.0 | 20.8–23.2 | Kidney and renal pelvis | 23.1 | 21.2–25.0 |
| Other, ill-defined, and unknown | 18.7 | 18.0–19.4 | Other, ill-defined, and unknown | 20.2 | 19.1–21.3 | Bladder | 18.7 | 17.0–20.4 |
| Bladder | 18.5 | 17.8–19.2 | Bladder | 18.4 | 17.3–19.5 | Other, ill-defined, and unknown | 17.4 | 15.8–19.0 |
| Non-Hodgkin Lymphoma | 17.4 | 16.7–18.1 | Non-Hodgkin Lymphoma | 16.1 | 15.1–17.1 | Non-Hodgkin Lymphoma | 17.0 | 15.4–18.6 |
| Corpus uteri | 12.5 | 11.9–13.1 | Corpus uteri | 13.3 | 12.4–14.2 | Pancreas | 13.2 | 11.8–14.6 |
| Thyroid | 12.5 | 11.9–13.1 | Thyroid | 12.7 | 11.7–13.7 | Corpus uteri | 12.2 | 10.8–13.6 |
| Pancreas | 11.9 | 11.4–12.4 | Pancreas | 12.1 | 11.2–13.0 | Thyroid | 10.8 | 9.3–12.3 |
| Female Breast (In Situ only) | 11.5 | 11.0–12.0 | Other nervous system | 9.5 | 8.7–10.3 | Liver and bile duct | 8.7 | 7.6–9.8 |
| Other nervous system | 9.7 | 9.2–10.2 | Liver and bile duct | 9.0 | 8.3–9.7 | Other nervous system | 7.9 | 6.7–9.1 |
| Liver and bile duct | 8.7 | 8.2–9.2 | Female Breast (In Situ only) | 8.3 | 7.6–9.0 | Female Breast (In Situ only) | 7.4 | 6.3–8.5 |
| Mortality | ||||||||
| Cancer | AAMR | 95% CI | Cancer | AAMR | 95% CI | Cancer | AAMR | 95% CI |
| Lung & bronchus | 43.2 | 42.1–44.3 | Lung & bronchus | 53.1 | 51.3–54.9 | Lung & bronchus | 48.8 | 46.1–51.5 |
| Colon & rectum | 15.4 | 14.8–16.0 | Colon & rectum | 18.0 | 16.9–19.1 | Colon & rectum | 17.6 | 16.0–19.2 |
| Other, Ill-defined & Unknown | 13.5 | 12.9–14.1 | Other, Ill-defined & Unknown | 15.8 | 14.8–16.8 | Other, Ill-defined & Unknown | 15.6 | 14.1–17.1 |
| Female Breast | 12.6 | 12.0–13.2 | Female Breast | 12.0 | 11.1–12.9 | Pancreas | 13.1 | 11.7–14.5 |
| Pancreas | 10.7 | 10.2–11.2 | Pancreas | 11.4 | 10.6–12.2 | Female Breast | 11.8 | 10.5–13.1 |
| Prostate | 8.3 | 7.8–8.8 | Prostate | 8.1 | 7.4–8.8 | Prostate | 9.5 | 8.3–10.7 |
| Leukemias | 7.0 | 6.6–7.4 | Leukemias | 7.5 | 6.8–8.2 | Leukemias | 6.9 | 5.9–7.9 |
| Non-Hodgkin Lymphoma | 6.0 | 5.6–6.4 | Liver | 6.7 | 6.1–7.3 | Liver | 6.5 | 5.5–7.5 |
| Liver | 5.9 | 5.5–6.3 | Non-Hodgkin Lymphoma | 5.9 | 5.3–6.5 | Non-Hodgkin Lymphoma | 6.2 | 5.2–7.2 |
| Brain & Other Nervous System | 4.9 | 4.5–5.3 | Bladder | 5.3 | 4.7–5.9 | Kidney & renal pelvis | 5.9 | 5.0–6.8 |
| Bladder | 4.6 | 4.2–5.0 | Kidney & renal pelvis | 5.2 | 4.6–5.8 | Brain & Other Nervous System | 5.7 | 4.7–6.7 |
| Kidney & renal pelvis | 4.4 | 4.1–4.7 | Brain & Other Nervous System | 4.8 | 4.2–5.4 | Ovary | 4.2 | 3.4–5.0 |
| Esophagus | 4.0 | 3.7–4.3 | Esophagus | 4.5 | 4.0–5.0 | Esophagus | 4.1 | 3.3–4.9 |
| Ovary | 4.0 | 3.7–4.3 | Ovary | 3.7 | 3.2–4.2 | Bladder | 3.5 | 2.8–4.2 |
| Other digestive organs | 3.4 | 3.1–3.7 | Oral Cavity & Pharynx | 3.4 | 2.9–3.9 | Other digestive organs | 3.4 | 2.7–4.1 |
AAIR=Age-adjusted incidence rate; AADR=Age-adjusted mortality rate